SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-008973
Filing Date
2022-02-23
Accepted
2022-02-23 16:31:36
Documents
13
Period of Report
2022-02-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156087-8k_inmunebio.htm   iXBRL 8-K 25296
2 PRESS RELEASE, DATED FEBRUARY 23, 2022 ea156087ex99-1_inmunebio.htm EX-99.1 8409
  Complete submission text file 0001213900-22-008973.txt   211898

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20220223.xsd EX-101.SCH 3036
4 XBRL LABEL FILE inmb-20220223_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE inmb-20220223_pre.xml EX-101.PRE 22597
7 EXTRACTED XBRL INSTANCE DOCUMENT ea156087-8k_inmunebio_htm.xml XML 3711
Mailing Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037
Business Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 22664282
SIC: 2836 Biological Products, (No Diagnostic Substances)